Literature DB >> 8099807

Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

H M Coley1, W B Amos, P R Twentyman, P Workman.   

Abstract

This study highlights the usefulness of laser scanning confocal microscopy in the examination of subcellular disposition of anthracyclines in tumour cell lines. The distribution of anthracycline compounds has been studied in two pairs of parental and multidrug resistant (MDR) cell lines. For the parental EMT6 mouse mammary tumour cell line EMT6/P treated with doxorubicin (DOX) the anthracycline fluorescence was shown to be predominantly nuclear but with some particulate cytoplasmic fluorescence and very low levels of plasma membrane staining. In the same experiments much fainter fluorescence was seen for the EMT6/AR1.0 MDR subline which hyperexpresses P-glycoprotein. The loss of nuclear fluorescence was comparatively greater than loss of cytoplasmic fluorescence. For the human large cell lung cancer line COR-L23/P cellular DOX disposition was markedly nuclear with nuclear membrane staining and diffuse cytoplasmic fluorescence. For the MDR line COR-L23/R, which lacks P-glycoprotein expression, DOX fluorescence was reduced in the nucleus compared with the parental line, but an intense area of perinuclear staining was seen consistent with localisation to the Golgi apparatus. The morpholinyl-substituted analogue MR-DOX achieved very similar subcellular distribution in both parental and MDR lines, consistent with its retention of activity in the latter. The presence of verapamil during anthracycline exposure increased the intensity of fluorescence in the MDR lines, particularly in the nucleus. Relatively little effect was seen in the parental lines. Confocal microscopy provides high resolution images of the subcellular distribution of anthracyclines in parent and MDR cell lines. Differences in drug disposition in various cell lines may provide insights into the mechanism of multidrug resistance and suggest strategies for its therapeutic circumvention.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099807      PMCID: PMC1968480          DOI: 10.1038/bjc.1993.244

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Cytofluorescence localization of adriamycin and daunorubicin.

Authors:  M J Egorin; R C Hildebrand; E F Cimino; N R Bachur
Journal:  Cancer Res       Date:  1974-09       Impact factor: 12.701

3.  Cytofluorescence localization of anthracycline antibiotics.

Authors:  M J Egorin; R E Clawson; J L Cohen; L A Ross; N R Bachur
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

4.  Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  A Krishan; M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

5.  Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.

Authors:  T Tsuruo; H Iida; Y Kitatani; K Yokota; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

6.  Comparative cytotoxicities of various morpholinyl anthracyclines.

Authors:  D G Streeter; D L Taylor; E M Acton; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Cellular accumulation and disposition of aclacinomycin A.

Authors:  M J Egorin; R E Clawson; L A Ross; N M Schlossberger; N R Bachur
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

8.  Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein.

Authors:  M A Barrand; T Rhodes; M S Center; P R Twentyman
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

9.  The in vitro effects and cross-resistance patterns of some novel anthracyclines.

Authors:  P R Twentyman; N E Fox; K A Wright; P Workman; M J Broadhurst; J A Martin; N M Bleehen
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

10.  9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.

Authors:  C A Scott; D Westmacott; M J Broadhurst; G J Thomas; M J Hall
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  34 in total

1.  Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.

Authors:  U Beyer; B Rothern-Rutishauser; C Unger; H Wunderli-Allenspach; F Kratz
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter.

Authors:  S Paul; L M Breuninger; K D Tew; H Shen; G D Kruh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.

Authors:  Marlon S Mathews; Van Vo; En-Chung Shih; Genesis Zamora; Chung-Ho Sun; Steen J Madsen; Henry Hirschberg
Journal:  J Environ Pathol Toxicol Oncol       Date:  2012       Impact factor: 3.567

4.  Intracellular distribution of anthracyclines in drug resistant cells.

Authors:  G Arancia; A Calcabrini; S Meschini; A Molinari
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

5.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

6.  Intracellular trafficking of a pH-responsive drug metal complex.

Authors:  Azadeh Kheirolomoom; Elizabeth S Ingham; Joel Commisso; Neveen Abushaban; Katherine W Ferrara
Journal:  J Control Release       Date:  2016-10-13       Impact factor: 9.776

7.  Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport.

Authors:  E Crivellato; L Candussio; A M Rosati; G Decorti; F B Klugmann; F Mallardi
Journal:  Histochem J       Date:  1999-10

8.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

9.  Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.

Authors:  Zahia Ouar; Marcelle Bens; Caroline Vignes; Marc Paulais; Claudine Pringel; Jocelyne Fleury; Francçoise Cluzeaud; Roger Lacave; Alain Vandewalle
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

10.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

Authors:  Alex M Chen; Min Zhang; Dongguang Wei; Dirk Stueber; Oleh Taratula; Tamara Minko; Huixin He
Journal:  Small       Date:  2009-12       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.